A near-monopoly national-security nuclear supplier with booming SMR and medical-isotope optionality—yet priced for flawless execution.
Overview
BWXT is a highly specialized nuclear technology and manufacturing company with an unusually wide moat, operating at the intersection of national security, clean energy, and nuclear medicine. Its business is split into Government Operations (the earnings backbone) and Commercial Operations (diversification and high-growth optionality). In Government Operations, BWXT is the sole-source producer of nuclear reactors and precision components for the U.S. Navy’s nuclear fleet, supported by long-term DOE/Naval Nuclear Propulsion Program contracts; it is also expanding into special nuclear materials and domestic enrichment initiatives while providing technical services at high-consequence national sites. Commercial Operations (2025 revenue $853M) includes CANDU refurbishment components in Canada, SMR component manufacturing (notably GE Hitachi’s BWRX-300), and BWXT Medical’s fast-scaling isotope platform (Mo-99, Yb-176, Lu-177). In 2025 BWXT delivered record performance (revenue $3.20B, EPS $4.01, backlog $7.3B), but the stock’s very high valuation implies “priced for perfection” execution expectations.